RxDoctor Payments DataLook up a doctor →

Daniel Claassen, MD

Neurology · Nashville, TNNPI 1821101411

Payments from drug & device makers

$3,496,166in general payments, 2019–2025

Across 520 payments — averaging $6723.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$2.1M
  • AbbVie$977K
  • Neurocrine Biosciences, Inc.$148K
  • PTC Therapeutics, Inc.$127K
  • Teva Pharmaceuticals USA, Inc.$84K
  • Lundbeck LLC$24K
  • plus $70K from 12 others
$26,266in research payments, 2019–2025

Across 23 payments — averaging $1142.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Teva Pharmaceuticals USA, Inc.$26K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,496,166 in reported general payments places this provider in the 95th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$8,574
Medicare patients
52
Services billed
62

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →